131 related articles for article (PubMed ID: 11686525)
1. Serum tenascin-C is an indicator of inflammatory bowel disease activity.
Riedl S; Tandara A; Reinshagen M; Hinz U; Faissner A; Bodenmüller H; Buhr HJ; Herfarth C; Möller P
Int J Colorectal Dis; 2001 Sep; 16(5):285-91. PubMed ID: 11686525
[TBL] [Abstract][Full Text] [Related]
2. Relationship between levels of angiogenic and lymphangiogenic factors and the endoscopic, histological and clinical activity, and acute-phase reactants in patients with inflammatory bowel disease.
Algaba A; Linares PM; Fernández-Contreras ME; Ordoñez A; Trápaga J; Guerra I; Chaparro M; de la Poza G; Gisbert JP; Bermejo F
J Crohns Colitis; 2013 Dec; 7(11):e569-79. PubMed ID: 23642997
[TBL] [Abstract][Full Text] [Related]
3. Correlation between soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) expression and endoscopic activity in inflammatory bowel diseases.
Jung YS; Park JJ; Kim SW; Hong SP; Kim TI; Kim WH; Cheon JH
Dig Liver Dis; 2012 Nov; 44(11):897-903. PubMed ID: 22721842
[TBL] [Abstract][Full Text] [Related]
4. Antibodies against glycoprotein 2 are novel markers of intestinal inflammation in patients with an ileal pouch.
Werner L; Sturm A; Roggenbuck D; Yahav L; Zion T; Meirowithz E; Ofer A; Guzner-Gur H; Tulchinsky H; Dotan I
J Crohns Colitis; 2013 Dec; 7(11):e522-32. PubMed ID: 23639628
[TBL] [Abstract][Full Text] [Related]
5. Mucosal tenascin C content in inflammatory and neoplastic diseases of the large bowel.
Riedl S; Kadmon M; Tandara A; Hinz U; Möller P; Herfarth C; Faissner A
Dis Colon Rectum; 1998 Jan; 41(1):86-92. PubMed ID: 9510316
[TBL] [Abstract][Full Text] [Related]
6. C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study.
Henriksen M; Jahnsen J; Lygren I; Stray N; Sauar J; Vatn MH; Moum B;
Gut; 2008 Nov; 57(11):1518-23. PubMed ID: 18566104
[TBL] [Abstract][Full Text] [Related]
7. [Neopterin in assessing the activity of inflammatory bowel diseases: ulcerative colitis and Crohn's disease].
Ciećko-Michalska I; Fedak D; Mach T
Przegl Lek; 2010; 67(12):1262-5. PubMed ID: 21591350
[TBL] [Abstract][Full Text] [Related]
8. Correlation between serological biomarkers and endoscopic activity in patients with inflammatory bowel disease.
Miranda-García P; Chaparro M; Gisbert JP
Gastroenterol Hepatol; 2016 Oct; 39(8):508-15. PubMed ID: 27020243
[TBL] [Abstract][Full Text] [Related]
9. Serum procalcitonin differentiates inflammatory bowel disease and self-limited colitis.
Herrlinger KR; Dittmann R; Weitz G; Wehkamp J; Ludwig D; Schwab M; Stange EF; Fellermann K
Inflamm Bowel Dis; 2004 May; 10(3):229-33. PubMed ID: 15290916
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic value of serum procalcitonin in determining the activity of inflammatory bowel disease.
Oruç N; Ozütemiz O; Osmanoğlu N; Ilter T
Turk J Gastroenterol; 2009 Mar; 20(1):9-12. PubMed ID: 19330729
[TBL] [Abstract][Full Text] [Related]
11. Circulating levels of leptin, adiponectin, resistin, and ghrelin in inflammatory bowel disease.
Karmiris K; Koutroubakis IE; Xidakis C; Polychronaki M; Voudouri T; Kouroumalis EA
Inflamm Bowel Dis; 2006 Feb; 12(2):100-5. PubMed ID: 16432373
[TBL] [Abstract][Full Text] [Related]
12. Anti-inflammatory effects of pancreatitis associated protein in inflammatory bowel disease.
Gironella M; Iovanna JL; Sans M; Gil F; Peñalva M; Closa D; Miquel R; Piqué JM; Panés J
Gut; 2005 Sep; 54(9):1244-53. PubMed ID: 15870231
[TBL] [Abstract][Full Text] [Related]
13. Detection of calprotectin in inflammatory bowel disease: Fecal and serum levels and immunohistochemical localization.
Fukunaga S; Kuwaki K; Mitsuyama K; Takedatsu H; Yoshioka S; Yamasaki H; Yamauchi R; Mori A; Kakuma T; Tsuruta O; Torimura T
Int J Mol Med; 2018 Jan; 41(1):107-118. PubMed ID: 29115397
[TBL] [Abstract][Full Text] [Related]
14. Increased Tryptophan Metabolism Is Associated With Activity of Inflammatory Bowel Diseases.
Nikolaus S; Schulte B; Al-Massad N; Thieme F; Schulte DM; Bethge J; Rehman A; Tran F; Aden K; Häsler R; Moll N; Schütze G; Schwarz MJ; Waetzig GH; Rosenstiel P; Krawczak M; Szymczak S; Schreiber S
Gastroenterology; 2017 Dec; 153(6):1504-1516.e2. PubMed ID: 28827067
[TBL] [Abstract][Full Text] [Related]
15. Urinary excretion of N-methylhistamine as a marker of disease activity in inflammatory bowel disease.
Winterkamp S; Weidenhiller M; Otte P; Stolper J; Schwab D; Hahn EG; Raithel M
Am J Gastroenterol; 2002 Dec; 97(12):3071-7. PubMed ID: 12492192
[TBL] [Abstract][Full Text] [Related]
16. Ulcerative colitis, Crohn's disease, and irritable bowel syndrome have different profiles of extracellular matrix turnover, which also reflects disease activity in Crohn's disease.
Mortensen JH; Manon-Jensen T; Jensen MD; Hägglund P; Klinge LG; Kjeldsen J; Krag A; Karsdal MA; Bay-Jensen AC
PLoS One; 2017; 12(10):e0185855. PubMed ID: 29028807
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of noninvasive evaluations in monitoring inflammatory bowel disease activity: A prospective study in China.
Chen JM; Liu T; Gao S; Tong XD; Deng FH; Nie B
World J Gastroenterol; 2017 Dec; 23(46):8235-8247. PubMed ID: 29290660
[TBL] [Abstract][Full Text] [Related]
18. Peripheral Lymphocytes of Patients with Inflammatory Bowel Disease Have Altered Concentrations of Key Apoptosis Players: Preliminary Results.
Neubauer K; Woźniak-Stolarska B; Krzystek-Korpacka M
Biomed Res Int; 2018; 2018():4961753. PubMed ID: 30515402
[TBL] [Abstract][Full Text] [Related]
19. Serum prohepcidin levels in chronic inflammatory bowel diseases.
Nagy J; Lakner L; Poór VS; Pandur E; Mózsik G; Miseta A; Sipos K
J Crohns Colitis; 2010 Dec; 4(6):649-53. PubMed ID: 21122575
[TBL] [Abstract][Full Text] [Related]
20. Nonenzymatic Serum Antioxidant Capacity in IBD and Its Association with the Severity of Bowel Inflammation and Corticosteroids Treatment.
Neubauer K; Kempinski R; Matusiewicz M; Bednarz-Misa I; Krzystek-Korpacka M
Medicina (Kaunas); 2019 Apr; 55(4):. PubMed ID: 30986917
[No Abstract] [Full Text] [Related]
[Next] [New Search]
